Anti-RET Proto-oncogene Monoklonale Antilichaam (Kloon: RET/2662)

The Ret proto-oncogene is structurally related to the growing family of tyrosine kinase transmembrane receptors and is involved in GDNF signaling. RET expression is reported in several regions of the central nervous system; in the developing cranial nerve ganglia and a subset of cells within dorsal root ganglia, in motor neurons in the spinal cord and hindbrain, in neuro-retina and the growing tips of the renal collecting ducts in developing kidney.Alterations in RETgene are associated with diseases including papillary thyroid carcinoma, multiple endocrine neoplasia (type 2A and 2B), familial medullary thyroid carcinoma, and a congenital developmental disorder known as Hirschsprung's disease.

Cadherin family member 12 (CDHF12) ; Cadherin related family member 16 (CDHR16) ; ELKS; HSCR1; Hydroxyaryl protein kinase; MEN2A; MEN2B; MTC1; Multiple endocrine neoplasia and medullary thyroid carcinoma 1; Oncogene RET; Proto-oncogene c-Ret; Proto-oncogene tyrosine-protein kinase receptor ret; PTC; R

RET

5979

P07949

Human

Recombinant fragment (around aa 702-848) of human RET protein (exact sequence is proprietary)

RET/2662

ELISA

200 μg/mL of Ab Purified from Bioreactor Concentrate by Protein A/G. Prepared in 10mM PBS with 0.05% BSA & 0.05% azide. Also available WITHOUT BSA & azide at 1.0mg/mL.

Antibody with azide - store at 2 to 8°C. Antibody without azide - store at -20 to -80°C. Antibody is stable for 24 months. Non-hazardous.

ELISA (For coating, order antibody without BSA)

Mouse IgG2b, kappa